Neurocrine Biosciences Inc (NBIX)
Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
News
Neurocrine Biosciences Inc Tops Charts with Remarkable Financial Growth in 2023
Neurocrine Biosciences Inc has Slipped into minus at NBIX in the fiscal span ending March 31 2023
Steady rise by NBIX amid the fourth quarter of 2022 earnings season
Steller 59.848%, rise in Revenues at the company over the April to June 30 2022 time-frame